Cataract Consent Form
For adult patients with mental capacity to give valid consent to Cataract removal and new lens implant / Phacoemulsification and IOL
Standards & Guidance
Our range of high-quality guidance helps to maintain standards in the planning, practice and commissioning of patient care. Our clinical guidelines provide evidence-based recommendations across all aspect of care or of eye conditions; Concise Practice Points make recommendations for less frequent and targeted clinical situations, succinctly describing the scientific and clinical evidence alongside expert input to enhance clinician and patient decision making. Our Commissioning guidance supports eye units to develop services to meet local population needs.
Measuring follow up timeliness and risk for performance reporting, improvement actions and targeting failsafe procedures in England
This document describes the recommended method for ophthalmology providers to measure delays to follow-up care using a patient administration system (PAS) field which can submit data to NHS Digital to assess national performance, provide data for managing individual patients and services, and allow reporting to commissioners and trust executive teams. This allows the calculation of the Portfolio of Eye Health & Care follow up indicator of % of hospital outpatient appointments that occur within 25% of their intended follow up period, including rescheduling or hospital initiated cancellations14. In order to ensure consistency across providers on derived metrics, it is essential that data collected from any PAS has been recorded in a consistent and equitable manner.
Genomics Services
This document is to keep members informed of developments with the UK genomics services. However, this is a very fast moving area with rapid developments driven at the national level. The information in this document is correct as at February 2020.
Guide to the RCOphth Review Service
On occasion, healthcare organisations may have concerns regarding some aspects of delivery of an ophthalmology service or they may wish to have an objective assessment of how their service is performing. Find out what the RCOphth Service Review can do for you.
Ophthalmic Special Order Products
The Ophthalmic Special Order Products list relates to topical and oral ophthalmic agents. For injectable agents refer to Medusa injectable guide. The list is colour coded as follows: green for specials suitable for initiation by primary care; amber for specials initiated by secondary care and can be continued by primary care; red for specials prescribed by secondary care only.
Intravitreal injection therapy
Advice about performing all intravitreal injection therapy (IVT) as safely as possible, whilst supporting the requirement for innovative and efficient models of care to deal with the continuing increase in demand.
Ophthalmology outpatients – safe and efficient processes
This document outlines some key principles and aims to support national programmes involved in reconfiguration of ophthalmology services for improvement such as the National Elective Care Transformation programme, Getting it Right First Time and Right Care.
RCOphth Statement on Ethambutol Toxicity
NHS Improvement has highlighted two recent incidents of severe visual loss due to delayed diagnosis of optic neuropathy from ethambutol. In 2015, 5758 cases of tuberculosis were notified in England and ethambutol is frequently prescribed in its initial phase of treatment. Although ethambutol optic neuropathy is rare, members are strongly reminded of the possibility of this cause of preventable sight loss and to ensure that current guidance is followed.
Serum Eye Drops for the Treatment of Severe Ocular Surface Disease: Executive Summary
Dry eye disease is a global public-health problem with significant impact on quality of life. Serum Eye Drops (SED) contain many nutritional factors that aid therapeutics. Across the NHS There is variation in practice, inequality of access to SED service and no regulated monitoring outcome. This guideline sets out defined criteria for the use of Serum Eye Drops, monitoring of clinical and patient-reported outcomes to improve patient morbidity and standards of care.